Glutamate ionotropic receptor NMDA type subunit 2B-containing receptor (GluN2B-NMDAR)

The Glutamate ionotropic receptor NMDA type subunit 2B-containing receptor (GluN2B-NMDAR) is a specific subtype of the N-methyl-D-aspartate receptor family, distinguished by the inclusion of the GluN2B subunit [1, 4]. These receptors are heterotetrameric ligand-gated ion channels that mediate excitatory neurotransmission and are highly permeable to calcium ions [1, 3]. They play a critical role in synaptic plasticity, specifically in the induction of long-term potentiation (LTP) and long-term depression (LTD), which are the cellular foundations of learning and memory [4, 11]. In the adult brain, GluN2B-containing receptors are prominently expressed in the forebrain and are often localized at extrasynaptic sites, where their overactivation is a primary driver of excitotoxicity and neuronal apoptosis [2, 9, 13]. This pathological role links the receptor to various neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, major depressive disorder, and chronic pain [1, 2, 6, 7]. Pharmacologically, these receptors are targeted by negative allosteric modulators (NAMs) that bind to the amino-terminal domain (ATD) at the interface of the GluN1 and GluN2B subunits [2, 7, 8]. Such selective modulation aims to provide therapeutic benefits, such as neuroprotection or rapid antidepressant effects, while avoiding the severe dissociative and cognitive side effects associated with non-selective NMDA receptor antagonists [2, 6, 8].

Other names

NR2B-containing NMDA receptorGlutamate receptor ionotropic NMDA 2B-containing receptorGRIN2B-containing NMDA receptorGluRε2-containing NMDA receptorN-methyl-D-aspartate receptor subunit 2B-containing receptor

Negative allosteric modulation of the NMDA receptor complex by binding to the interface of the GluN1 and GluN2B amino-terminal domains (ATD), which stabilizes the receptor in a closed-channel state and reduces calcium influx [2, 7, 8].